Please login to the form below
Four Health and ARK among winners at PM Society Digital Awards
The awards celebrated its 10th year with biggest event yet
Democrats’ final pricing plan announced, 250 drugs targeted
Would allow US federal government to negotiate prices of key medicines
Insys gets bankruptcy court okay for Subsys sale
Opioid product was focus of racketeering charges
Breath test could predict response to immunotherapy
Study found device accurately predicted responses in lung cancer
J&J puts pressure on rivals with new Erleada okay in prostate cancer
FDA previously granted priority review in this indication
Bluebird Bio reveals further encouraging data for CALD gene therapy
Study shows continued benefit in treatment of rare disease
Takeda’s HAE drug Takhzyro backed by NICE
New treatment option for rare, hereditary disease
Distribution of Novartis’ generic Zantac halted due to carcinogen concerns
Ranitidine medicines found to contain cancer-causing substance
Q&A: Chris McPherson
PME interviews ENGINE | MHP's account director, health
-
Q&A: Jessica PaceyPME interviews the founder and chief executive of newly launched health comms agency, 67health
-
Who's calling the shots in European healthcare?Patients versus Pharma: industry too powerful, and too cosy with EMA, says Yannis Natsis
-
Roche wins FDA breakthrough for Gazyva in lupus nephritisDrug originally approved as a lymphoma treatment
-
Zenopa delivers Communiqué prizes to winnersPublicis Resolute's Georgina Chan, MGP's Peter Sayer and Celgene's Sara Jones win the prizes
-
Biogen loses another pipeline drug to toxicity concernsFollows discontinuation of Eisai-partnered Alzheimer's drug
-
FDA starts speedy review of Merck’s Ebola vaccineFirst company to file for approval in the US
-
Purdue Pharma files for bankruptcy after opioid settlementCompany has faced brunt of blame for fuelling epidemic
-
Novartis eyes potential new indication for CosentyxUnveils positive late-stage results in axial spondyloarthritis
-
Acceleron scraps rare muscular dystrophy drug Clinical profile not strong enough to push into late-stage testing
Latest appointments
-
Life announces two new hiresStrenghtens growing creative department
-
New hires at Bayer, Eisai and Accord HealthcareThe latest movers in pharma
-
New faces at 90TEN, Lucid Group and Porterhouse Latest movers in healthcare comms
-
Senior leadership moves announced at Publicis HealthNew roles will support European operations
-
Lucid Group announces new hires at its creative and digital agency Bluedog Follows group's success at Communiqué 2019
Featured jobs
- Client Services Director- Flexible Working
-
Negotiable
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 bonus benefits
-
Account Director – UK Office
-
Excellent salary and benefits
-
Senior Medical Writer
-
Competitive salary plus benefits
-
Events Executive
-
DOE
- Account Manager – Healthcare advertising
-
Salary TBC
Subscribe to our email news alerts
- Novartis eyes potential new indication for Cosentyx
- J&J's Tremfya filed for approval in US for psoriatic arthritis
- Envision Pharma Group relocates to support expansion
- Biogen loses another pipeline drug to toxicity concerns
- AZ, Merck’s Lynparza scores market-expanding clinical success
- Half of European cancer drug trials ‘biased’, says BMJ
PMHub
Attigo (part of the Mednet Group)
We are socially intuitive. Attigo deliver inspiring creative healthcare communications, whilst leading the way as partner of choice for socially-conscious...
Latest intelligence
- Report: Customer experience, shaping digital healthcare
- In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
- Encouraging signs in biomarker R&D
- The cancer immunotherapy firms ramping-up biomarker R&D...
- Programmatic methodology and why you should be using it
- What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...
Quick links
Infographics
